𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients

✍ Scribed by Mélanie Vallin; Olivier Guillaud; Isabelle Morard; Marie-Claude Gagnieu; Gilles Mentha; Mustapha Adham; Emmanuel Morelon; Olivier Boillot; Emiliano Giostra; Jérôme Dumortier

Book ID
110890487
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
181 KB
Volume
25
Category
Article
ISSN
0902-0063

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, tolerability, and efficacy of ev
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results
✍ Gary Levy; Heinz Schmidli; Jeffrey Punch; Elizabeth Tuttle-Newhall; David Mayer; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 grou

Conversion to sirolimus-based immunosupp
Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients
✍ Isabelle Morard; Jérôme Dumortier; Laurent Spahr; Antoine Hadengue; Pietro Majno 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

Sirolimus (SRL) has been proposed to replace calcineurin inhibitors (CNI) in case of CNI-induced toxicity. The aim of this study was to evaluate the efficacy and safety of conversion from CNI to SRL in maintenance liver transplantation (LT) patients. Between 2002 and 2006, conversion was performed i

Present state of immunosuppressive thera
Present state of immunosuppressive therapy in liver transplant recipients
✍ Russell H. Wiesner; John J. Fung 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 1 views

## Key Points 1. Our increasing understanding of the signaling pathways and cellular interactions in transplant immunobiology has facilitated targeted strategies using novel immunosuppressive agents. 2. The pattern of immunosuppressive drug use in the United States continues to change, and the chan

Conversion from a calcineurin inhibitor
Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial
✍ Paolo De Simone; Herold J. Metselaar; Lutz Fischer; Jérôme Dumortier; Karim Boud 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB

Calcineurin inhibitors (CNIs) contribute to renal dysfunction following liver transplantation. This prospective, randomized, multicenter, 6-month study (with an additional 6 months of follow-up) evaluated whether everolimus with CNI reduction or discontinuation would improve renal function in mainte